Kimberly-Clark agreed to buy Kenvue for about $40 billion, a bold move as the Tylenol maker faces unproven autism claims championed by the Trump administration. Kenvue’s shares jumped about 20 percent in premarket trading on the news, while Kimberly-Clark fell more than 10 percent. The cash-and-stock deal would give Kimberly-Clark shareholders roughly 54 percent of the combined company, which the firms expect to generate $32 billion in revenue and $7 billion in operating profit, with nearly $2 billion in cost cuts. Closing is targeted for the second half of 2026, pending approvals.

Prepared by Christopher Adams and reviewed by editorial team.